ECRI updates its adverse event collection system

With an eye on sharing “the most important patient safety lessons” with the public as well as its members, the ECRI Institute Patient Safety Organization (PSO) has come out with a new version of its adverse-event collection and reporting system.

The new iteration is compliant with the Agency for Healthcare Research and Quality (AHRQ) Common Formats Version 1.1 and includes the latest formats for health IT reporting, according to a statement.

The Plymouth Meeting, Pa.-based organization said it drew from its expertise in gathering patient-safety information to improve the forms its members use to report adverse events, adding that its PSO collects, analyzes and addresses events from a wide sampling of healthcare settings.

It also said the PSO’s reporting system is designed to capture near misses as well as serious adverse events and has more than 100,000 events in its database.

“ECRI Institute PSO encourages IT vendors to map to the Common Formats to accelerate sharing, aggregation and learning,” said Barbara G. Rebold, RN, the PSO’s director of operations. “This allows PSOs and AHRQ to analyze and report information for improvement nationally.”

ECRI Institute PSO is part of a national PSO system established in 2005 with the passing of the the Patient Safety and Quality Improvement Act, which has the goal of encouraging clinicians and healthcare organizations to report patient-safety concerns without fear of recrimination.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.